Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Orv Hetil ; 163(2): 53-62, 2022 01 09.
Article in Hungarian | MEDLINE | ID: mdl-34999571

ABSTRACT

Összefoglaló. A landiolol intravénásan alkalmazandó, kifejezetten cardioselectiv, gyors hatású és rövid felezési ideju béta-1-receptor-blokkoló, mely elsosorban negatív chronotrop és inotrop hatással bír, vérnyomáscsökkento hatása elhanyagolható. Foleg hemodinamikailag instabil állapotú, supraventricularis ritmuszavarban szenvedo betegek kamrafrekvenciájának csökkentésére használható. Nagy esetszámú, randomizált vizsgálatok igazolták hatékonyságát szívmutétek után jelentkezo pitvarfibrilláció megelozésében, valamint súlyos akut szívelégtelenségben és szívmutétek posztoperatív szakában jelentkezo pitvari tachyarrhythmiák kezelésében. Ezek mellett kisebb vizsgálatok alapján a használata biztonságosnak tunik akut myocardialis infarctusban, hatékony szeptikus állapotú, pitvarfibrillációban szenvedo betegek kamrafrekvencia- és ritmuskontrolljára, valamint nem cardialis mutétek esetén a pitvarfibrilláció prevenciójára és kezelésére. Sikerrel alkalmazható elektromos vihar esetén is, és jól használható angiográfiás coronaria-CT-vizsgálat elott az optimális szívfrekvencia elérésére. A gyógyszer 2016 óta Európában, 2018 óta Magyarországon is elérheto. Orv Hetil. 2022; 163(2): 53-62. Summary. Landiolol is an intravenous, selective beta-1-receptor blocking agent with rapid onset of action and ultra-short half-life that has a predominant negative chronotropic and only mild negative inotropic effect without significant reduction of blood pressure. Landiolol is indicated to control the ventricular heart rate predominantly in patients with hemodynamic instability due to supraventricular tachyarrhythmia. Large randomized controlled trials have proven the efficacy of landiolol in the prevention of atrial fibrillation and atrial tachyarrhythmias in severe acute heart failure or post-cardiac surgery. Based on lower case-number studies, the administration of landiolol has been proven to be efficient and safe in rhythm and rate control in atrial fibrillation complicating acute myocardial infarction, sepsis, and in the prevention of atrial fibrillation in non-cardiac surgery. Landiolol may be used in electrical storm, and even during coronary CT-angiography to achieve an optimal heart rate for imaging. The drug is available in Europe since 2016 and in Hungary since 2018. Orv Hetil. 2022; 163(2): 53-62.


Subject(s)
Atrial Fibrillation , Myocardial Infarction , Critical Care , Heart Rate , Humans , Morpholines , Urea/analogs & derivatives
2.
Langenbecks Arch Surg ; 407(2): 845-860, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34402959

ABSTRACT

BACKGROUND: Bariatric surgery is more effective in the management of morbid obesity and related comorbidities than is conservative therapy. Pylorus-preserving single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-SG) is a modified duodenal switch technique. Gastric plication (GP) is an alternate to SG. METHODS: Morbidly obese (BMI of > 40, or > 35 in the presence of diabetes or prediabetes) patients were recruited and operated on to perform SADI with GP. Complications related to surgery were recorded to assess the feasibility of the procedure. Weight-loss outcomes were analysed to determine efficacy. Minnesota Multiphasic Personality Inventory 2 (MMPI-2) was recorded after 1 year of follow-up, and test scales were used to describe physiological phenomena. RESULTS: Seventeen middle-aged (mean: 40 years) patients were involved in our study; 15 of them were females. The mean duration of surgery was 205 min. There were no complications of conversion, death, bleeding, VTE or 30-day readmission to hospital. We did experience CD4a (pulmonary insufficiency due to chronic lung disease) and a CD3b (anastomosis leakage treated laparoscopically) complications. Vomiting occurred in three cases (CD1). Obesity-related comorbidities showed favourable resolution rates (77.8% for hypertension, 81.2% for dyslipidaemia, 100% for diabetes at the 1-year follow-up). Weight-loss outcomes were favourable (53.20 EWL%, and 35.58 TWL% at 1-year follow-up). Greater weight loss caused significantly higher levels of Depression (t(13.958) = - 2.373; p = 0.00; p < 0.05) and Low Positive Emotions (t(13.301) = - 2.954; p = 0.00; p < 0.05) and Introversion/Low Positive Emotionality (t(13.408) = - 1.914; p = 0.02; p < 0.05) in MMPI-2 data. CONCLUSION: According to our safety study, SADI-GP is a promising malabsorptive procedure, but a long-term high-volume case series or a randomised controlled trial is necessary to evaluate complication rates and weight-loss outcomes. Emotional dysregulation is common among bariatric surgery patients according to personality inventory data; therefore, psychological follow-up and psychotherapeutic support are necessary for weight-loss maintenance.


Subject(s)
Gastric Bypass , Laparoscopy , Obesity, Morbid , Duodenum/surgery , Female , Gastrectomy/adverse effects , Gastric Bypass/adverse effects , Humans , Laparoscopy/adverse effects , Male , Middle Aged , Obesity, Morbid/complications , Obesity, Morbid/surgery , Retrospective Studies
3.
Orv Hetil ; 160(43): 1714-1718, 2019 Oct.
Article in Hungarian | MEDLINE | ID: mdl-31630550

ABSTRACT

Bariatric surgery is more effective in the management of morbid obesity and related comorbidities than conservative therapy. There are two main groups, restrictive and malabsorptive procedures. Laparoscopic gastric plication with pylorus-preserving loop duodenoileal bypass is classified into the latter group. It should be considered as the modernized variant of the classical Scopinaro procedure. In this article, the method is presented by a case report. Orv Hetil. 2019; 160(43): 1714-1718.


Subject(s)
Bariatric Surgery/methods , Gastric Bypass/methods , Gastroplasty/methods , Laparoscopy/methods , Obesity, Morbid/surgery , Stomach/surgery , Adult , Bariatric Surgery/adverse effects , Female , Gastric Bypass/adverse effects , Gastroplasty/adverse effects , Humans , Laparoscopy/adverse effects , Obesity, Morbid/diagnosis , Pylorus , Treatment Outcome
4.
Brain Res ; 1648(Pt A): 438-444, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27543337

ABSTRACT

INTRODUCTION: A different innervation pattern of proximal and distal muscles from the contra- and ipsilateral motor circuits raises the question as to whether bilateral, contra- and ipsilateral subthalamic stimulation may have different effects on the distal and proximal movements of the upper limb. To answer this question, we performed kinematic analyzes in patients with Parkinson's disease. METHODS: Twenty-eight Parkinsonian patients treated by bilateral subthalamic stimulation were examined with an age-matched control group of 28 healthy subjects. They performed 14s of finger tapping, hand grasping and pronation-supination. The patient group performed these sessions in four conditions (BOTH ON, BOTH OFF, CONTRA ON, IPSI ON) after withdrawal of dopaminergic medication for 12h and a fifth condition after taking medication (BOTH ON-MED ON). A motion sensor with a three-dimensional gyroscope was worn on the index finger. Speed, amplitude, rhythm and decrement of movements were calculated and compared across these conditions. RESULTS: Speed and amplitude of the more distal movements were improved similarly by contra- and bilateral stimulation. Bilateral stimulation was more effective than contralateral stimulation for the more proximal movements. Contra- and bilateral stimulation ameliorated the rhythm similarly in each movement task. Decrement of distal and proximal movements was not affected by the stimulation conditions. CONCLUSION: This is the first study to show that the outcome of bi- and unilateral subthalamic stimulation on proximal and distal upper limb movements should be evaluated separately postulating the different somatotopic organization of subloops in the cortico-basal ganglia motor circuits.


Subject(s)
Deep Brain Stimulation/methods , Motor Activity , Parkinson Disease/physiopathology , Subthalamic Nucleus/physiopathology , Upper Extremity/physiopathology , Biomechanical Phenomena , Female , Fingers/physiopathology , Hand Strength , Humans , Male , Middle Aged , Recovery of Function
5.
Ideggyogy Sz ; 66(3-4): 115-20, 2013 Mar 30.
Article in Hungarian | MEDLINE | ID: mdl-23750427

ABSTRACT

BACKGROUND AND PURPOSES: In advanced Parkinson's disease, medically refractory motor fluctuation or medically resistant tremor considerably affects quality of life. However, these symptoms can be mostly successfully treated by deep brain stimulation. We analyzed the efficacy of bilateral subthalamic stimulation in our patients with Parkinson's disease. METHODS: We assessed the clinical data of ten patients who have been treated in the Department of Neurology, Semmelweis University and have been operated in the National Institute of Neurosciences between 2008 and 2011. The Hoehn-Yahr scale score, the Unified Parkinson's Disease Rating Scale score and the Parkinson's Disease Questionnaire 39, as well as the dose of antiparkinson medication were documented prior to and one year after surgery. RESULTS: Patient condition improved according to the Hoehn-Yahr scale, approximately by two stages. The dose of antiparkinson medication could be reduced by 63.4% (p = 0.005) post operation. Unified Parkinson's Disease Rating Scale scores decreased by 70.9% (p = 0.005). 12 hours after medication withdrawal, execution of daily activity improved by 57.1% (p < 0.01) and motor functions developed by 79.1% (p < 0.01). Duration of dyskinesias decreased by 62.5% (p = 0.018), duration of akinesia diminished by 87.5% (p = 0.005). Quality of life rose by 41.6% (p < 0.01). Neuropsychological tests detected improvement in verbal memory. CONCLUSION: With deep brain stimulation, the dosage of antiparkinson medication could be significantly reduced, with considerable improvements in motor function and quality of life. Although the number of patients is still low, good results have been established by careful patient selection, precise neurosurgical procedure and by appropriate programming and patient care.


Subject(s)
Activities of Daily Living , Antiparkinson Agents/administration & dosage , Deep Brain Stimulation , Parkinson Disease/therapy , Psychomotor Performance , Quality of Life , Subthalamic Nucleus , Adult , Aged , Deep Brain Stimulation/methods , Electrodes, Implanted , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Subthalamic Nucleus/physiopathology , Subthalamic Nucleus/surgery , Treatment Outcome
6.
Ideggyogy Sz ; 66(11-12): 365-71, 2013 Nov 30.
Article in Hungarian | MEDLINE | ID: mdl-24555235

ABSTRACT

In the course of Parkinson's disease, advanced and late stages can be distinguished. In the advanced stage, levodopa has good effect on motor symptoms, but patient care is often hindered by levodopa-induced complications such as motor fluctuation and dyskinesias. In the late stage levodopa response becomes poor, falls, dementia and psychotic symptoms appear and patients often need hospitalization. In the advanced stage, the quality of life may be improved better by device-aided therapy than by best oral medical treatment. The alternatives are apomorhin pump, levodopa carbidopa intestinal gel with pump and deep brain stimulation. The therapy plan should be based on the principle: "the right treatment, to the right patient, at the right time".


Subject(s)
Antiparkinson Agents/therapeutic use , Apomorphine/therapeutic use , Carbidopa/therapeutic use , Deep Brain Stimulation , Dyskinesia, Drug-Induced/therapy , Levodopa/therapeutic use , Parkinson Disease/therapy , Quality of Life , Administration, Oral , Age Factors , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/adverse effects , Apomorphine/administration & dosage , Apomorphine/adverse effects , Carbidopa/administration & dosage , Carbidopa/adverse effects , Cognition Disorders/etiology , Cognition Disorders/prevention & control , Dopamine Agents/therapeutic use , Drug Tolerance , Duodenum , Dyskinesia, Drug-Induced/etiology , Dyskinesia, Drug-Induced/prevention & control , Gels , Humans , Infusion Pumps, Implantable , Levodopa/administration & dosage , Levodopa/adverse effects , Parkinson Disease/complications , Parkinson Disease/drug therapy , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...